IDH1 and central nervous system cancer: This effect strongly impacted adaptive anti-tumor immunity, as combination therapy of a mutant IDH1 inhibitor (BAY1436032) with PD-1 inhibition significantly extended overall survival of glioma-bearing mice (42).